![person holding white and orange plastic bottle](/assets/images/download.222c5fdd2a@512w.jpg)
AstraZeneca's Enhertu: FDA Approval for HER2-Positive Tumors
The successful development and potential expanded use of Enhertu underscore AstraZeneca's commitment to advancing innovative therapies for cancer patients.
Charts and financial information provided by TradingView, a popular charting & trading platform. Check out even more advanced features or grab charts for your website.
All Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.
The successful development and potential expanded use of Enhertu underscore AstraZeneca's commitment to advancing innovative therapies for cancer patients.
AstraZeneca has agreed to acquire Icosavax for up to $1.1 billion, signaling a major expansion in its vaccine and infectious disease portfolio.